Jianying Zhou

发表

Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations

He-long Zhang, N. Yang, Sanyuan Sun, 2022, JTO clinical and research reports.

Lorlatinib for Previously Treated ALK -Positive Advanced NSCLC: Primary Ef ﬁ cacy and Safety From a Phase 2 Study in People ’ s Republic of China

C. Bai, He-long Zhang, Jian-hua Chang, 2022 .

Ef ﬁ cacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study

Ying Cheng, R. Guo, Yiping Zhang, 2022 .

Safety, Clinical Activity, and Pharmacokinetics of Al ﬂ utinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation

D. Zhong, N. Yang, S. Qin, 2020 .

Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.

J. Shentu, Jianying Zhou, Jianya Zhou, 2011, Lung cancer.

Tocilizumab overcomes chemotherapy resistance in mesenchymal stem-like breast cancer by negating autocrine IL-1A induction of IL-6

Jenny C. Chang, W. Qian, A. Chan, 2022, NPJ breast cancer.

Effects of Icotinib on Advanced Non-Small Cell Lung Cancer with Different EGFR Phenotypes

Jianying Zhou, Hui Fang, Sheng-wu Huang, 2014, Cell Biochemistry and Biophysics.

Tocilizumab overcomes chemotherapy resistance in mesenchymal stem-like breast cancer by negating autocrine IL-1A induction of IL-6

Jenny C. Chang, W. Qian, A. Chan, 2022, npj Breast Cancer.

Lorlatinib for Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer: Primary Efficacy and Safety From a Phase 2 Study in China.

Ying Cheng, C. Bai, He-long Zhang, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies.

T. Wang, D. Zhong, Yanqiu Zhao, 2023, Lung cancer.

ID:1882 Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3

Ying Cheng, H. Wakelee, T. Mok, 2020 .

Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study.

X. Chen, Pengxiang Wu, R. Guo, 2023, The Lancet. Respiratory medicine.

Efficacy and safety of befotertinib (D-0316) in patients with EGFR T790M mutated non-small cell lung cancer that had progressed after prior EGFR TKI therapy: A phase 2, multicenter, single-arm, open-label study.

Qingshan Li, Ying Cheng, R. Guo, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

1372O CLDN 18.2-targeted CAR-T cell therapy in patients with cancers of the digestive system

Zhi Peng, J. Gong, S. Ge, 2021, Annals of Oncology.